MicroRNAs (miRNAs) are a group of small noncoding RNAs (about 18-24 nucleotides in length) that function as post-transcriptional regulators in eukaryotic cells [1] . This small RNA can bind to the 3'UTR of the target mRNA [2] . Binding of the miRNA can hinder translation of mRNA by promoting degradation or inducing deadenylation [3] . Dysregulation of miRNA expression is thought to play a part in abnormal gene expression in cancer cells [8, 12] . miRNAs are transcribed by RNA polymerase II and III [4] . The primary miRNAs are long precursor RNA molecules. Before being transported into the cytoplasm, the precursor molecules are processed by cellular nucleases, such as Drosha, into shorter premiRNAs. In the cytoplasm, the pre-miRNAs are processed by RNA III (Dicer) into the functional mature form (single-stranded, ~22 nucleotides) [5] . Mature miRNAs are usually associated with a cellular complex that is similar to the RNA-induced silencing complex that participates in RNA interference [6, 7] .
We recently evaluated the miRNA expression patterns in squamous cell carcinoma (SCC) of the tongue [8] . Of the 156 examined human mature miRNAs, miR-184 was significantly increased in the tumor cells in comparison with the normal epithelial cells of the tongue. High miR-184 levels were not only detected in the tumor tissues, but also in the plasma of patients with tongue SCC. Decreased plasma levels of miR-184 were observed in patients after surgical removal of the primary tumor. The presentation of miR-184 in our patient samples prompted us to suggest that it is a potential oncogenic miRNA in tongue SCC. We also evaluated the functional role of miR-184 in tongue SCC. We observed that inhibiting miR-184 would promote apoptosis as well as hinder cell proliferation in cultured tongue SCC cells.
The first identified miRNA, lin-4, was discovered in 1993 as a small noncoding RNA that regulates gene expression in Caenorhabditis elegans [9] . The second identified miRNA, lethal-7 (let-7), was also found in C. elegans in 2000 [10] . Later on, similar miRNAs were identified in the human genome. In cancer cells, miRNAs could act as tumor suppressors or oncogenes. Tumor-suppressing miRNAs could inhibit the expression of oncogenic genes being overexpressed in cancers. For example, in patients with chronic lymphocytic leukemia (CLL), suppression of tumor-suppressing miRNAs miR-15A and miR-16-1 results in the up-regulation of the B-cell CLL/lymphoma 2 (BCL2) gene that controls cell proliferation in CLL [11] . In comparison with the tumor-suppressive miRNAs, oncogenic miRNAs could promote tumorigenesis by down-regulating the tumor-suppressor genes. For example, overexpression of the 131 oncogenic miRNA mir-17-92 cluster could promote cell proliferation by targeting apoptosis-inducing genes [12] . miRNA profiling is now carried out in different human malignancies. Similar to the profiling of gene expression patterns, we see that different cancer types could be distinguished by their differential miRNA expression patterns.
Over the past decades, only a small proportion of miRNAs has been evaluated in human cancer cells. For miR-184, only minimal information is available. Expression of miR-184 in mammalian cells was reported in 2006. High expression was observed in suprabasal cells of the corneal epithelium in the mouse model [13] . Strong expression of miR-184 was observed in the epithelial cells of the cornea in comparison with the germinative layers. Similar to other oncogenic miRNAs, the regulatory mechanism for miR-184
is not yet elucidated. Recently, Nomura et al. established a linkage between miR-184 expression and methylation-imprinting miR-184 in the mouse model [14] . They identified that expression of miR-184 is partly regulated by the methyl CpG-binding protein 2 (MeCP2), a transcription repressor that binds to the methylated CpG sequence. Since methylation imbalance is a common feature of cancers cells, it is interesting to examine the methylation status of the regulatory regions of human miR-184 and examine the correlations with the expression of miR-184.
Our previous understanding of the central dogma of genetics contains only three elements: DNA, RNA, and protein. We typically employ dysregulation or altered function in these three elements to explain the abnormal phenotype of cancer cells. However, we may encounter unexplained situations in which errors or abnormalities in these three elements are not identified. In the future, new insights or answers might be found with the development of epigenetics and the identification of miRNAs. Further studies are warranted to establish the role of miRNAs in cancers and the possible intercorrelation with the central dogma of genetics.
